Personalized Medicine News and Research

RSS

National Quantum Computing Centre launches Insights Paper exploring quantum computing's transformative potential in healthcare and pharmaceuticals

Today, the National Quantum Computing Centre (NQCC) launched its first Insights Paper, "The convergence of healthcare and pharmaceuticals with quantum computing: A new fronter in medicine", exploring how quantum computing could enable a step-change in medicine and healthcare delivery over the coming decades.

From NQCC 4 Apr 2025

Gut bacteria may reduce the effectiveness of common medications

A new study, published today in Nature Chemistry by researchers from the University of Pittsburgh and Yale University, shows how common gut bacteria can metabolize certain oral medications that target cellular receptors called GPCRs, potentially rendering these important drugs less effective.

3 Apr 2025

Mount Sinai launches AI center to revolutionize small molecule drug discovery

The Icahn School of Medicine at Mount Sinai has launched the AI Small Molecule Drug Discovery Center, a bold endeavor that harnesses artificial intelligence (AI) to revolutionize drug development.

2 Apr 2025

Transformative potential of AI to enhance coronary heart disease detection

Announcing a new article publication for Cardiovascular Innovations and Applications journal. Coronary heart disease (CHD), the most common cause of mortality globally, poses a formidable challenge to modern healthcare systems.

2 Apr 2025

A new blood test could improve how Alzheimer’s disease is diagnosed

The blood test for eMTBR-tau243 shows strong correlation with tau pathology, enhancing Alzheimer's diagnosis and monitoring cognitive decline effectively.

1 Apr 2025

Blood test offers insight into Alzheimer's stage and severity

A newly developed blood test for Alzheimer's disease not only aids in the diagnosis of the neurodegenerative condition but also indicates how far it has progressed, according to a study by researchers at Washington University School of Medicine in St. Louis and Lund University in Sweden.

31 Mar 2025

Novel PET imaging method quantifies brain inflammation enzyme

A novel PET imaging approach can effectively quantify a key enzyme associated with brain inflammation, according to research published in the March issue of The Journal of Nuclear Medicine.

28 Mar 2025

US Patent Office grants Closed Loop Medicine key patents for cardiometabolic capabilities in GLP-1 and Direct Oral Anti-Coagulants (DOAC) therapies

Closed Loop Medicine Ltd., a leader in AI-enabled precision medicines, today announced the expansion of its US patent portfolio. Strengthening its cardiometabolic treatment portfolio, the Company now has patents covering advancements in GLP-1 therapies for obesity and diabetes, and direct oral anticoagulants (DOACs) for cardiovascular health.

25 Mar 2025

Researchers reveal link between placental DNA methylation and neuropsychiatric disorders

An international team led by UPV/EHU and Biobizkaia reveals the relationship between placental DNA methylation and certain neuropsychiatric disorders.

20 Mar 2025

$1 million CPRIT grant focuses on AI to improve prostate cancer outcomes

Erzsébet Merényi, a statistics research professor at Rice University, and co-investigators at The University of Texas MD Anderson Cancer Center Pratip Bhattacharya, professor of cancer systems imaging, and Dr. Patrick Pilié, assistant professor of genitourinary medical oncology, were awarded $1 million by the Cancer Prevention and Research Institute of Texas (CPRIT) to develop artificial intelligence (AI) tools that can identify lethal forms of prostate cancer earlier and improve treatment selection.

18 Mar 2025

WIN Consortium revolutionizing precision oncology for cancer patients

A new precision oncology paper was published in Oncotarget, Volume 16, on March 12, 2025, titled "Worldwide Innovative Network (WIN) Consortium in Personalized Cancer Medicine: Bringing next-generation precision oncology to patients."

18 Mar 2025

AI-based neural network revolutionizes cancer treatment predictions

A first-of-its-kind artificial intelligence (AI)-based neural network can rapidly analyze and interpret millions of cells from a patient sample, predicting molecular changes in the tissue.

18 Mar 2025

Yale research supports MRD detection for post-treatment lung cancer care

In the continuing evolution of personalized medicine, a new Yale study has found evidence to support the value of a tool that measures the presence of cancer-derived molecules in the blood of patients with lung cancer years after their treatment.

17 Mar 2025

Novel regulators in digestive tract disease progression and treatment

This new article published in Genes & Diseases highlights the critical role of tRNA-derived small RNAs (tsRNAs) in digestive tract diseases, positioning these molecules as potential biomarkers for diagnosis, prognosis, and targeted therapies. The comprehensive review explores the biogenesis, classification, and biological functions of tsRNAs, shedding light on their influence over cellular processes such as translation regulation, epigenetic modification, and protein interactions.

11 Mar 2025

Deciphering the tumor-immune interplay in endometrial carcinoma

A new review article published in Genes & Diseases sheds light on the complex molecular mechanisms through which tumor-infiltrating immune cells regulate endometrial carcinoma (EC). As one of the most prevalent gynecological cancers, EC continues to challenge researchers and clinicians due to its dynamic interaction with the immune microenvironment.

11 Mar 2025

Exploring the relationship between non-coding RNAs and oxidative stress in cancer progression

A new review article published in Genes & Diseases explores the intricate relationship between non-coding RNAs and oxidative stress in cancer progression shedding new light on the mechanisms that drive tumor development.

5 Mar 2025

Anti-malarial drug pyronaridine could be repurposed to treat cancer

Can a drug that's used to treat malaria be repurposed to fight cancer? Researchers at The University of Texas at El Paso have secured a patent for the anti-malarial drug pyronaridine to do just that. Pyronaridine has been used to treat the mosquito-borne infectious disease for over 30 years.

3 Mar 2025